These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11668426)

  • 21. Prevention of venous thromboembolism after acute ischemic stroke.
    Kamphuisen PW; Agnelli G; Sebastianelli M
    J Thromb Haemost; 2005 Jun; 3(6):1187-94. PubMed ID: 15946209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
    Prandoni P; Simioni P; Pagnan A
    Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacoeconomics of deep vein thrombosis treatment.
    Shorr AF
    Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
    Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
    Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia.
    Reilly MP; Weiss R; Askenase A; Tuite C; Soulen M; Mohler ER
    Vasc Med; 2000; 5(4):239-42. PubMed ID: 11213236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin].
    Marx A; Huhle G; Hoffmann U; Wang LC; Schüle B; Jani L; Harenberg J
    Z Orthop Ihre Grenzgeb; 1999; 137(6):536-9. PubMed ID: 10666863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial treatment of venous thromboembolism.
    McRae SJ; Ginsberg JS
    Circulation; 2004 Aug; 110(9 Suppl 1):I3-9. PubMed ID: 15339875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of subcutaneous hirudins.
    Deitcher SR
    Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S27-31. PubMed ID: 14593980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low molecular weight heparins in the long-term treatment of venous thromboembolism.
    Liapis CD; Daskalopoulos ME; Daskalopoulou SE
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):495-500. PubMed ID: 12124561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism.
    Turpie AG; Mason JA
    Expert Opin Pharmacother; 2002 May; 3(5):575-98. PubMed ID: 11996636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of venous thromboembolism in the elderly.
    Spyropoulos AC; Merli G
    Drugs Aging; 2006; 23(8):651-71. PubMed ID: 16964988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of venous thromboembolism: challenging the unfractionated heparin standard.
    Nutescu E; Singh-Khalsa M;
    Pharmacotherapy; 2004 Aug; 24(8 Pt 2):127S-131S. PubMed ID: 15334858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of venous thromboembolism in cancer patients.
    Lee AY
    Thromb Res; 2001 Jun; 102(6):V195-208. PubMed ID: 11516453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of recombinant hirudins in the management of thrombotic disorders.
    Fischer KG
    BioDrugs; 2004; 18(4):235-68. PubMed ID: 15244501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
    Eriksson BI; Ekman S; Kalebo P; Zachrisson B; Bach D; Close P
    Lancet; 1996 Mar; 347(9002):635-9. PubMed ID: 8596376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy.
    McColl MD; Greer IA
    Curr Opin Pulm Med; 2004 Sep; 10(5):371-5. PubMed ID: 15316434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and economic aspects of managing venous thromboembolism in the outpatient setting.
    Agnelli G; Becattini C
    Semin Hematol; 2001 Apr; 38(2 Suppl 5):58-66. PubMed ID: 11449344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.